| Title |
JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma
|
|---|---|
| Published in |
Journal of Neuro-Oncology, March 2018
|
| DOI | 10.1007/s11060-018-2831-7 |
| Pubmed ID | |
| Authors |
Toshihiko Wakabayashi, Atsushi Natsume, Junki Mizusawa, Hiroshi Katayama, Haruhiko Fukuda, Minako Sumi, Ryo Nishikawa, Yoshitaka Narita, Yoshihiro Muragaki, Takashi Maruyama, Tamio Ito, Takaaki Beppu, Hideo Nakamura, Takamasa Kayama, Shinya Sato, Motoo Nagane, Kazuhiko Mishima, Yoko Nakasu, Kaoru Kurisu, Fumiyuki Yamasaki, Kazuhiko Sugiyama, Takanori Onishi, Yasuo Iwadate, Mizuhiko Terasaki, Hiroyuki Kobayashi, Akira Matsumura, Eiichi Ishikawa, Hikaru Sasaki, Akitake Mukasa, Takayuki Matsuo, Hirofumi Hirano, Toshihiro Kumabe, Nobusada Shinoura, Naoya Hashimoto, Tomokazu Aoki, Akio Asai, Tatsuya Abe, Atsuo Yoshino, Yoshiki Arakawa, Kenichiro Asano, Koji Yoshimoto, Soichiro Shibui, Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG) |
X Demographics
The data shown below were collected from the profiles of 22 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 9 | 41% |
| United Kingdom | 1 | 5% |
| Spain | 1 | 5% |
| Italy | 1 | 5% |
| Ecuador | 1 | 5% |
| India | 1 | 5% |
| Portugal | 1 | 5% |
| Mexico | 1 | 5% |
| Unknown | 6 | 27% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 14 | 64% |
| Scientists | 3 | 14% |
| Practitioners (doctors, other healthcare professionals) | 3 | 14% |
| Science communicators (journalists, bloggers, editors) | 2 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 54 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 9 | 17% |
| Researcher | 4 | 7% |
| Student > Doctoral Student | 4 | 7% |
| Student > Ph. D. Student | 3 | 6% |
| Other | 3 | 6% |
| Other | 11 | 20% |
| Unknown | 20 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 39% |
| Neuroscience | 4 | 7% |
| Chemical Engineering | 1 | 2% |
| Immunology and Microbiology | 1 | 2% |
| Unspecified | 1 | 2% |
| Other | 2 | 4% |
| Unknown | 24 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 February 2022.
All research outputs
#2,270,041
of 25,837,817 outputs
Outputs from Journal of Neuro-Oncology
#124
of 3,302 outputs
Outputs of similar age
#47,310
of 350,999 outputs
Outputs of similar age from Journal of Neuro-Oncology
#2
of 100 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,302 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 350,999 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 100 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.